Pharmaceutical compositions
CA 2109952 C · Owner: Lipoxen Technologies Limited · Inventors: Gregoriadis, Gregory
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
Polysaccharides comprising at least 5 sialic acid residues per molecule and used to increase the circulation time, decrease the immunogenicity and/or increase the stability in vivo of pharmaceutically active compounds. The pharmaceutically active compound may be a foreign protein which is covalently bound to the polysaccharide. Alternatively the active compound may be associated with a drug delivery system (DDS) for instance a macro-molecular , DDS or a particulate DDS such as liposomes. The, polysaccharide is usually a bacterial polysaccharide e.g. a glycolipid or a , derivative thereof for instance polysaccharide B or E. Coli K1 N.meningitidis, Moraxella liquifaciens or Pasteurella …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed June 8, 1992 and granted November 18, 2003. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended June 8, 2012.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by June 8, 2014.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.